Literature DB >> 16954312

Impact of sample size on the performance of multiple-model pharmacokinetic simulations.

Vincent H Tam1, Samer Kabbara, Rosa F Yeh, Robert H Leary.   

Abstract

Monte Carlo simulations are increasingly used to predict pharmacokinetic variability of antimicrobials in a population. We investigated the sample size necessary to provide robust pharmacokinetic predictions. To obtain reasonably robust predictions, a nonparametric model derived from a sample population size of >/=50 appears to be necessary as the input information.

Mesh：

Substances：

Year:  2006        PMID： 16954312      PMCID： PMC1635223          DOI： 10.1128/AAC.00337-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

Authors:  R Jelliffe; D Bayard; M Milman; M Van Guilder; A Schumitzky
Journal:  Ther Drug Monit       Date:  2000-06       Impact factor: 3.681

2.  Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling.

Authors:  Vincent H Tam; Sandra L Preston; George L Drusano
Journal:  Pharmacotherapy       Date:  2003-12       Impact factor: 4.705

3.  Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.

Authors:  Joseph L Kuti; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Journal:  J Clin Pharmacol       Date:  2003-10       Impact factor: 3.126

4.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.

Authors:  Ben M Lomaestro; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Arnold Louie; Ben M Lomaestro; George L Drusano
Journal:  Pharmacotherapy       Date:  2003-03       Impact factor: 4.705

7.  Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.

Authors:  P G Ambrose; S M Bhavnani; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

8.  Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.

Authors:  G L Drusano; S L Preston; C Hardalo; R Hare; C Banfield; D Andes; O Vesga; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Authors:  Joseph L Kuti; Naomi R Florea; Charles H Nightingale; David P Nicolau
Journal:  Pharmacotherapy       Date:  2004-01       Impact factor: 4.705

10.  Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

Authors:  Joseph L Kuti; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191
  10 in total
  13 in total

1.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Authors:  Ana Motos; Joseph L Kuti; Gianluigi Li Bassi; Antoni Torres; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.

Authors:  Regis Kreitchmann; Alice Stek; Brookie M Best; Edmund Capparelli; JiaJia Wang; David Shapiro; Nahida Chakhtoura; Mark Mirochnick; Ahizechukwu C Eke
Journal:  Contraception       Date:  2021-08-15       Impact factor: 3.375

4.  Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.

Authors:  Ahizechukwu C Eke; Jiajia Wang; Khadija Amin; David E Shapiro; Alice Stek; Elizabeth Smith; Nahida Chakhtoura; Michael Basar; Kathleen George; Katherine M Knapp; Esaú C João; Kittipong Rungruengthanakit; Edmund Capparelli; Sandra Burchett; Mark Mirochnick; Brookie M Best
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.

Authors:  Mathias Wittau; Jan Scheele; Max Kurlbaum; Claas Brockschmidt; Anna M Wolf; Evelyn Hemper; Doris Henne-Bruns; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

6.  Deep-Learning-Based Neural Tissue Segmentation of MRI in Multiple Sclerosis: Effect of Training Set Size.

Authors:  Ponnada A Narayana; Ivan Coronado; Sheeba J Sujit; Jerry S Wolinsky; Fred D Lublin; Refaat E Gabr
Journal:  J Magn Reson Imaging       Date:  2019-10-18       Impact factor: 4.813

7.  Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections.

Authors:  Nicolas Garbez; Litaty Mbatchi; Steven C Wallis; Laurent Muller; Jeffrey Lipman; Jason A Roberts; Jean-Yves Lefrant; Claire Roger
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

Review 8.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

9.  Population pharmacokinetics of teicoplanin in children.

Authors:  V Ramos-Martín; S Paulus; S Siner; E Scott; K Padmore; P Newland; R J Drew; T W Felton; F Docobo-Pérez; B Pizer; F Pea; M Peak; M A Turner; M W Beresford; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

10.  Predicting sample size required for classification performance.

Authors:  Rosa L Figueroa; Qing Zeng-Treitler; Sasikiran Kandula; Long H Ngo
Journal:  BMC Med Inform Decis Mak       Date:  2012-02-15       Impact factor: 2.796
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.